What factors affect the sufficient dose of rituximab?

rituximab is a drug used to destroy the subtype of immune cells of the body known as B cells. Drugs do not discriminate between healthy and patients of cells, which is useful in the treatment of autoimmune diseases such as rheumatoid arthritis and cancer such as leukemia and Hodgkin's lymphoma. Rituximab is also used as an immunosuppressant outside the designation that helps prevent rejection of organs, although no convincing studies have been effective for this application that show that the drug is effective. Rituximab dose recommendations vary depending on the condition to be treated, as well as age, patient's weight, drug regime and health. The assessment of the appropriate initial dose of rituximab and the subsequent increase in the dose must be performed with maximum accuracy and careful premedication, since the drug often causes infusion reactions that have the potential to be fatal.

WSPEPIC SOLUTION Drugs IntravenThe initial dose of rituximab 50 mg per hour, with an increase in 50 mg per hour used every half an hour, should be used if there are no signs of infusion or hypersensitivity. If the reaction develops, the drug infusion should be slowed or stopped until the reaction disappears, and then increased at half the previous speed. The final dose should not exceed 400 mg per hour. If the patient does not show any signs of infusion reaction during the first course of treatment, subsequent treatment may be administered at 100 mg per hour and increased at the same dose every half an hour.

In the first treatment of CD20-positive, leaf B-cell B-cell non-hour or low lymphoma, the initial regime of 375 mg/m2 should be administered intravenously on the first day of each chemotherapeutic cycle until eight treatments. The same regimen should be used for patients with diffuse large B-cell non-ohgkin lymphoma. If the spacier shows either a complete or partial response to the therapy, it should be followedAn eight -day weekly maintenance in which rituximab is used as monotherapy. In the treatment of CD20-positive low or leaf B-cell lymphoma B-cells that relapse or persist, the dose of rituximab should be 375 mg/m2 for a week for four and eight weeks. Re -treatment of the same conditions requires only four weekly treatment at the same level of dosing.

Dose recommendations are somewhat different in using a drug to replenish chemotherapy in chronic lymphocytic leukemia. The same dose of rituximab 375 mg/m2 should be administered the day before the start of chemotherapy with fludarabin and cyclophosphamide. One importance, however, is that the first day of cycles two and six chemotherapy require a higher dose of 500 mg/m2.

in patients with slightly severe to severe rheumatoid arthritis, which adequately respond to agonist therapy from at least one tumor factor (TNF) can be used combined medicinal therapy. In addition to using methotrexate should be a dose of 1,000 mg rituximab pDue once a week for two weeks, according to the patient's reaction, other treatment courses were considered for another 24 weeks. Re -treatment should be performed earlier than every 16 weeks.